KMT2A and neoplasm: MLL binds to the promoter regions of cyclin-dependent kinase inhibitors (CDKis) p18Ink4c (CDKN2C) and p27Kip1 (CDKN1B), maintaining the expression of these genes and inhibiting tumour formation [53].